MTOR and renal cell carcinoma: Specific to mTOR, rapamycin and its rapalogs temsirolimus (CCI779, Wyeth), everolimus (RAD001, Novartis), and ridaforolimus (AP23573/MK-8669, ARIAD-Merck) (Fig. 4) are known to be effective against renal cell carcinoma, and are being investigated for the treatment of other malignancies [79].